Abstracts tagged "IL-6"

Abstract Number: 982 • 2018 ACR/ARHP Annual Meeting
In the Presence of IL-18, IL-10 but Not IL-6 Induces IFN-γ Production and the Surface Expression of TRAIL on NK Cells
Kojiro Sato, Yoshimi Aizaki, Hiroaki Yazawa and Toshihide Mimura, Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan
Background/Purpose: Adult-onset Still’s disease (AOSD) is a systemic inflammatory disease, the cause of which is largely unknown. AOSD has been recently classified as one of…
Abstract Number: 2900 • 2018 ACR/ARHP Annual Meeting
Impaired TCR Signaling Paves the Way for Cytokine Hyper-Responsiveness in Arthritogenic T Cells
Judith Ashouri¹, Lih-Yun Hsu¹, Dmitry Rychkov², Marina Sirota², Lisa Lattanza³, Eric Hansen³, Julie Zikherman¹ and Arthur Weiss¹, ¹Rosalind Russell and Ephraim P. Engleman Rheumatology Research Center, Department of Medicine, Division of Rheumatology, University of California, San Francisco, San Francisco, CA, ²Pediatrics, Institute for Computational Health Sciences, University of California, San Francisco, San Francisco, CA, ³Orthopedic Surgery, University of California, San Francisco, San Francisco, CA
Background/Purpose: The inability to identify relevant arthritogenic CD4 T cells in patients and in murine disease models has limited our understanding of disease initiating events…
Abstract Number: 992 • 2018 ACR/ARHP Annual Meeting
Epigallocatechin-3-Gallate (EGCG) Suppresses Systemic Inflammation By Inhibiting IL-6-Induced STAT3 Activation in Cultured Hepatocytes and in Liver Tissue of Adjuvant-Induced Arthritis (AIA) Rats
Anil K. Singh¹, Sabrina Fechtner², Dorothy Wang², Mukesh Chourasia³ and Salahuddin Ahmed^2,4, ¹Washington State University, College of Pharmacy, Spokane, WA, ²Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, ³Department of Pharmacoinformatics,, National lnstitute of Pharmaceutical Education and Research, Hajipur,, India, ⁴Division of Rheumatology, University of Washington, Division of Rheumatology, School of Medicine, Seattle, WA
Background/Purpose: In rheumatoid arthritis (RA), the pro-inflammatory cytokine interleukin-6 (IL-6) induces systemic inflammation by activating hepatocytes through IL-6 receptor (IL-6R)- mediated JAK/STAT3 signaling pathway. The…
Abstract Number: 1052 • 2018 ACR/ARHP Annual Meeting
Detection of Precursors of RANK- Osteoclast-like Cells (Olcs) in Peripheral Blood and Olcs in Bone Tissue from Rheumatoid Arthritis Patients
Kazuhiro Yokota¹, Shinya Tanaka², Miyoko Sekikawa², Yoshimi Aizaki¹, Kojiro Sato¹, Hiromi Oda² and Toshihide Mimura¹, ¹Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ²Department of Orthopaedic Surgery, Saitama Medical University, Saitama, Japan
Background/Purpose: Proinflammatory cytokines play an important role in bone destruction in rheumatoid arthritis (RA), as inferred by the efficacy of biologics. Previously, we reported that…
Abstract Number: 1053 • 2018 ACR/ARHP Annual Meeting
Synovial Inflammation Identifies Patients Clusters in Osteoarthritis
Hannah Labinsky¹, Paul Panipinto¹, Kaytlyn Ly², Deric Khuat², Bhanupriya Madarampalli³, Vineet Mahajan¹, Jonathan Clabeaux⁴, Kevin MacDonald⁴, Peter Verdin⁴, Jane H. Buckner² and Erika H. Noss³, ¹Medicine, Division of Rheumatology, University of Washington, Seattle, WA, ²Benaroya Research Institute at Virginia Mason, Seattle, WA, ³Rheumatology, University of Washington, Seattle, WA, ⁴Orthopedics, Virginia Mason Hospital, Seattle, WA
Background/Purpose: Synovial membrane inflammation is common in osteoarthritis (OA). Inflammation may be present at all disease stages, increases the risk of cartilage injury, and is…
Abstract Number: 1511 • 2018 ACR/ARHP Annual Meeting
The Relationship between Lipid Profile Changes and Inflammation across the Phase 3 Sarilumab Rheumatoid Arthritis (RA) Developmental Program
Christina Charles-Schoeman¹, Gregory St. John², Henry Leher², Toshio Kimura², Hubert van Hoogstraten³, Michael T. Nurmohamed⁴, Miguel Angel González-Gay⁵ and Edward C. Keystone⁶, ¹Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ³Sanofi Genzyme, Bridgewater, NJ, ⁴VU University Medical Center, Amsterdam, Netherlands, ⁵University Hospital Marques de Valdecilla, Santander, Spain, ⁶University of Toronto and Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Sarilumab showed superiority to placebo and adalimumab in Phase 3 trials. Serum lipids may be reduced in the setting of chronic inflammation associated with…
Abstract Number: 1521 • 2018 ACR/ARHP Annual Meeting
Anti-IL-6 Therapy Modulates Leptin in Patients with Rheumatoid Arthritis
Sara Remuzgo-Martínez¹, Fernanda Genre¹, Verónica Pulito-Cueto¹, Verónica Mijares¹, Leticia Lera-Gómez¹, Jaime Calvo-Alén², Ricardo Blanco¹, Oreste Gualillo³, Javier Llorca⁴, Santos Castañeda⁵, Raquel Lopez-Mejías¹ and Miguel Angel González-Gay^1,6,7, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, ²Rheumatology Department, Hospital Universitario Araba. Vitoria-Gasteiz, Alava, Spain, ³SERGAS (Servizo Galego de Saude) and IDIS (Instituto de Investigación Sanitaria de Santiago), The NEIRID Group (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Santiago University Clinical Hospital, Santiago de Compostela, Spain, Santiago de Compostela, Spain, ⁴Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, Santander, Spain, ⁵Hospital Universitario La Princesa, IIS-Princesa, Madrid, Spain, ⁶Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁷School of Medicine, University of Cantabria, Santander, Spain, Santander, Spain
Background/Purpose: Leptin is an adipokine that plays an important role in the regulation of body weight and also participates in immune homeostasis and inflammatory processes1,2.…
Abstract Number: 1528 • 2018 ACR/ARHP Annual Meeting
Unique Changes in Hemoglobin with Sarilumab Versus Adalimumab Are Independent of Better Disease Control in Patients with Rheumatoid Arthritis (RA)
Gerd R. Burmester¹, Owen Hagino², Qunming Dong³, Marina Stanislav⁴, Antonio Gomez-Centeno⁵, Carlo Selmi⁶, Tom W.J. Huizinga⁷, Erin Mangan⁸, Cem Gabay⁹ and Mark C. Genovese¹⁰, ¹Charité – University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany, ²Sanofi Genzyme, Bridgewater, NJ, ³Sanofi, Bridgewater, NJ, ⁴Scientific Research Institute of Rheumatology, Russian Academy of Medical Sciences, Moscow, Russian Federation, ⁵Corporació Sanitària Parc Taulí, Barcelona, Spain, ⁶Rheumatology and Clinical Immunology Unit, Humanitas Research Hospital, Rozzano (MI), Italy, ⁷Leiden University Medical Center, Leiden, Netherlands, ⁸Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁹University Hospitals of Geneva, Geneva, Switzerland, ¹⁰Stanford University Medical Center, Palo Alto, CA
Background/Purpose: Anemia (WHO criteria: Hemoglobin [Hb] levels <12.0 g/dL [females] or <13.0 g/dL [males]) is a common finding associated with increased joint inflammation in patients…
Abstract Number: 1550 • 2018 ACR/ARHP Annual Meeting
Improvement of HbA1c in Patients with Rheumatoid Arthritis and Diabetes Type 2 during Treatment with Tocilizumab
Christof Specker¹, Annette Alberding², Martin Aringer³, Gerd R. Burmester⁴, Jan-Paul Flacke⁵, Michael Hofmann⁶, Peter Kaestner⁷, Herbert Kellner⁸, Frank Moosig⁹, Maren Sieburg¹⁰, Hans-Peter Tony¹¹ and Gerhard Fliedner¹², ¹Rheumatology and Clinical Immunology, Universitätsklinikum Essen, Essen, Germany, ²Internal Rheumatology, Krankenhaus St. Josef, Wuppertal, Germany, ³Medicine III, University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany, ⁴Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, ⁵Rheumatology, Roche Pharma AG, Grenzach-Wyhlen, Germany, ⁶Rheumatology, Chugai Pharma Europe Ltd., Frankfurt, Germany, ⁷Rheumatology, Ambulantes Rheumazentrum, Erfurt, Germany, ⁸Ambulantes Rheumazentrum, Erfurt, Germany, ⁹Rheumatology Center Schleswig-Holstein Mitte, Neumuenster, Germany, ¹⁰Rheumatologische Gemeinschaftspraxis, Magdeburg, Germany, ¹¹Rheumatology/Immunology, Medizinische Klinik II, Universitätsklinik, Würzburg, Germany, ¹²Rheumatological Practice, Osnabrueck, Germany
Background/Purpose: Interleukin 6 (IL-6) and C-reactive protein (CRP) are independent risk factors for type 2 diabetes mellitus [1], and IL-6 plays a role in insulin…
Abstract Number: 1940 • 2018 ACR/ARHP Annual Meeting
Reductions in Absolute Neutrophil Count (ANC) with Sarilumab Resulting in Dose Delays or Dose Decreases: Effects on Efficacy and Safety
Jeffrey R. Curtis¹, Gregory St. John², Michael Pannucci², Yong Lin³, José A. Maldonado-Cocco⁴, Tom W.J. Huizinga⁵, Marina Stanislav⁶ and Paul Emery⁷, ¹University of Alabama, Birmingham, AL, ²Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ³Sanofi Genzyme, Bridgewater, NJ, ⁴Universidad de Buenos Aires, Buenos Aires, Argentina, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Research Rheumatology Institute n. a. V.A. Nassonova, Moscow, Russian Federation, ⁷University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom
Background/Purpose: In sarilumab randomized controlled trials (RCTs), dose delay and/or reduction was recommended for management of patients who developed neutropenia Grade (G) 3 (ANC ≥500…
Abstract Number: 1963 • 2018 ACR/ARHP Annual Meeting
Phenome Wide Association Study of IL6R Variant Identifies Drug Target for Cardiovascular Disease and Inflammation
Tianxi Cai^1,2,3, Yichi Zhang^1,3, Yuk-Lam Ho¹, Nicholas Link¹, Jiehuan Sun^1,3, Jie Huang^1,4, Tianrun Cai^1,2,4, Scott Damrauer⁵, Yuri Ahuja², Jacqueline Honerlaw¹, Jie Huang¹, Lauren Costa¹, Petra Schubert¹, Chuan Hong³, David Gagnon^1,6, Yan Sun⁷, Michael Gaziano^1,2,4, Peter Wilson^7,8, Kelly Cho^1,2,4, Philip Tsao⁹, Christopher J. O'Donnell^1,2 and Katherine P. Liao^1,2,4, ¹VA Boston Healthcare System, Boston, MA, ²Harvard Medical School, Boston, MA, ³Harvard T.H. Chan School of Public Health, Boston, MA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Corporal Michael Crescenz VA Medical Center, Perlman School of Medicine, University of Pennsylvania, Philadelphia, PA, ⁶Boston University School of Public Health, Boston, MA, ⁷Emory University Schools of Medicine and Public Health, Atlanta, GA, ⁸Atlanta VA Medical Center, Atlanta, GA, ⁹VA Palo Alto Health Care System, Department of Medicine, Stanford University School of Medicine, Stanford, CA
Background/Purpose: Individuals with an interleukin 6 receptor (IL6R) genetic variant not on IL6R blocking therapy have biomarker profiles similar to those treated with IL6R blockers. …
Abstract Number: 1985 • 2018 ACR/ARHP Annual Meeting
IL-1β Inhibits the Expression of Dickkopf-1, an Antagonist of the Wnt-β-Catenin Signaling Pathway: A Possible Role of Inflammasome in Dysregulation of Endochondral Ossification
Satoshi Yamasaki¹, Yusuke Yoshida², Katsuhiro Oi², Tatsuomi Kuranobu², Takaki Nojima², Hiroaki Ida³ and Eiji Sugiyama⁴, ¹Division of Rheumatology, Kurume University Medical Center, Fukuoka, Japan, ²Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan, ³Respiorogy, Neurology and Rheumatology, Kurume University School of Medicine, Kurume, Japan, ⁴Department of Clinical Immunology and Rheumatology, Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan
Background/Purpose: Aberrant endochondral bone formation in the physis is a unique bone lesion in neonatal-onset multisystem inflammatory disease (NOMID), also called chronic infantile neurologic cutaneous…
Abstract Number: 2509 • 2018 ACR/ARHP Annual Meeting
Long-Term Treatment with Sarilumab Plus Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs): Pooled Safety and Efficacy with over 4 Years’ Treatment
Mark C. Genovese¹, Hubert van Hoogstraten², Gregory St. John³, Qunming Dong², Juan José Gómez-Reino⁴, José A. Maldonado-Cocco⁵, Juan Carlos Salazar⁶, Tom W.J. Huizinga⁷ and Gerd R. Burmester⁸, ¹Stanford University Medical Center, Palo Alto, CA, ²Sanofi Genzyme, Bridgewater, NJ, ³Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁴Complejo Hospitalario Universitario de Santiago de Compostela, Santiago, Spain, ⁵School of Medicine, Buenos Aires University, Buenos Aires, Argentina, ⁶Riesgo de Fractura S.A - CAYRE, Bogotá, Colombia, ⁷Leiden University Medical Center, Leiden, Netherlands, ⁸Charité – University Medicine Berlin, Berlin, Germany
Background/Purpose: EXTEND (NCT01146652) is an ongoing open-label extension study enrolling patients completing five sarilumab originator studies (MOBILITY [NCT01061736]; TARGET [NCT01709578]; ASCERTAIN [NCT01768572]; ACT11575 [NCT01217814]; ONE…
Abstract Number: 2525 • 2018 ACR/ARHP Annual Meeting
Correlation Analysis between Sirukumab Exposure and Selected Safety Events Following Subcutaneous Administration Using Pooled Phase 3 Data in Rheumatoid Arthritis
Yan Xu¹, Yanli Zhuang¹, Chuanpu Hu¹, Benjamin Hsu², Zhenhua Xu¹, Amarnath Sharma¹ and Honghui Zhou¹, ¹Global Clinical Pharmacology, Janssen Research & Development, LLC, Spring House, PA, ²Immunology Clinical Development, Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: To characterize the exposure-response (ER) relationship between systemic exposure to sirukumab (an anti- interleukin-6 [IL-6] human monoclonal antibody) and the occurrence of selected safety…
Abstract Number: 317 • 2018 ACR/ARHP Annual Meeting
Imaging Biomarker Based Patient Stratification: Initial Data and Validation in Four Most Common Knee Arthritic Diseases
Olga Kubassova¹, Mikael Boesen², Adam Taylor³, Robert Riis⁴, Lars Hornum⁵, Henning Bliddal², Christine Ballegaard⁶ and Else Marie Bartels⁴, ¹R&D, IAG, Image Analysis Group, London, United Kingdom, ²Department of Rheumatology, The Parker Institute, Copenhagen University Hospital at Frederiksberg, Frederiksberg, Denmark, ³IAG, Image Analysis Group, London, United Kingdom, ⁴The Parker Institute, Copenhagen University Hospital at Frederiksberg, Frederiksberg, Denmark, ⁵Novo Nordisk A/S, Måløv, Denmark, ⁶The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen F, Denmark
Background/Purpose: Biomarker science has advanced to aid in distinguishing between different forms of arthritis: inflammatory arthritides such as rheumatoid arthritis (RA) and psoriatic arthritis (PsA)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].